NeuroD1 Dictates Tumor Cell Differentiation in Medulloblastoma.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
23 06 2020
Historique:
received: 06 09 2019
revised: 01 04 2020
accepted: 27 05 2020
entrez: 25 6 2020
pubmed: 25 6 2020
medline: 29 4 2021
Statut: ppublish

Résumé

Tumor cells are characterized by unlimited proliferation and perturbed differentiation. Using single-cell RNA sequencing, we demonstrate that tumor cells in medulloblastoma (MB) retain their capacity to differentiate in a similar way as their normal originating cells, cerebellar granule neuron precursors. Once they differentiate, MB cells permanently lose their proliferative capacity and tumorigenic potential. Differentiated MB cells highly express NeuroD1, a helix-loop-helix transcription factor, and forced expression of NeuroD1 promotes the differentiation of MB cells. The expression of NeuroD1 in bulk MB cells is repressed by trimethylation of histone 3 lysine-27 (H3K27me3). Inhibition of the histone lysine methyltransferase EZH2 prevents H3K27 trimethylation, resulting in increased NeuroD1 expression and enhanced differentiation in MB cells, which consequently reduces tumor growth. These studies reveal the mechanisms underlying MB cell differentiation and provide rationales to treat MB (potentially other malignancies) by stimulating tumor cell differentiation.

Identifiants

pubmed: 32579914
pii: S2211-1247(20)30762-2
doi: 10.1016/j.celrep.2020.107782
pmc: PMC7357167
mid: NIHMS1607415
pii:
doi:

Substances chimiques

Basic Helix-Loop-Helix Transcription Factors 0
Hedgehog Proteins 0
Histones 0
Nerve Tissue Proteins 0
Patched-1 Receptor 0
Ptch1 protein, mouse 0
Neurogenic differentiation factor 1 169238-82-8
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43
Ezh2 protein, mouse EC 2.1.1.43
Lysine K3Z4F929H6

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107782

Subventions

Organisme : NCI NIH HHS
ID : R01 CA178380
Pays : United States

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare no competing interests.

Auteurs

Yan Cheng (Y)

Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA; Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.

Shengyou Liao (S)

Bioinformatics Research Group, Chinese Academy of Sciences, Beijing, China.

Gang Xu (G)

Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.

Jian Hu (J)

Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA; Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.

Duancheng Guo (D)

Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.

Fang Du (F)

Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.

Alejandra Contreras (A)

Blood Cell Development and Function, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.

Kathy Q Cai (KQ)

Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.

Suraj Peri (S)

Biostatistics and Bioinformatics Research Facility, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.

Yuan Wang (Y)

Laboratory of Molecular Neuropathology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.

David C Corney (DC)

Genomics and Molecular Genetics, GENEWIZ Co., South Plainfield, NJ, USA.

Anne Marie Noronha (AM)

Genomics and Molecular Genetics, GENEWIZ Co., South Plainfield, NJ, USA.

Lianne Q Chau (LQ)

Tumor Initiation& Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Ginger Zhou (G)

Genomics and Molecular Genetics, GENEWIZ Co., South Plainfield, NJ, USA.

David L Wiest (DL)

Blood Cell Development and Function, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.

Alfonso Bellacosa (A)

Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.

Robert J Wechsler-Reya (RJ)

Tumor Initiation& Maintenance Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA.

Yi Zhao (Y)

Bioinformatics Research Group, Chinese Academy of Sciences, Beijing, China.

Zeng-Jie Yang (ZJ)

Cancer Biology Program, Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA. Electronic address: zengjie.yang@fccc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH